Behind the scenes of analytical development and control strategy of generic complex GLP-1 peptides

lior stern, R&D, TAPI, Netanya, Israel (Lior.stern@teva.co.il)

In the recent years GLP-1 based complex peptides drugs are an emerging segment in the pharmaceutical industry. This type of products bring both process and analytical challenges.

In order to achieve firm control strategy, an intensive analytical methods development, is required, thru a comprehensive methodology, applying several orthogonal and complimentary methods. This presentation is inviting you to explore our journey of identification, quantification and controlling more than 300 impurities applying various state of the art analytical techniques